Development of Saridegib Is Halted
Infinity Pharmaceuticals said its saridegib compound failed to meet primary endpoints in a phase II trial for the treatment of inoperable chondrosarcoma. Development of the drug is being halted, sending INFI lower by 27 percent before the bell on my tradeMONSTER platform.
Extorre Soars on Yamana Takeover
Extorre Gold Mines agreed to be purchased by Yamana Gold for about $4.16 a share in cash and stock. XG soars more than 55 percent on the news.
Product Mix Sours Results From DSW
DSW said earnings will be just $0.60 to $0.64 a share in the second quarter because shoppers are buying lower-margin items. That's less than last year's $0.74 result, and below the $0.76 expected by analysts. DSW drops 11 percent before the bell.
Groupon Upgraded By Morgan Stanley
Groupon was upgraded to "Overweight" from "Equal weight" by Morgan Stanley, which cited the company's strong market position. GRPN is higher by almost 5 percent in the premarket.
Body Central Plunges on Weak Outlook
Body Central expects second-quarter profit of $0.19 to $0.21 a share, missing the $0.27 consensus estimate. The retailer's full-year guidance was also poor, and BODY is getting slammed by more than 26 percent in early trading!
More From optionMONSTER
- U.S., Europe stocks higher as euro gains
- Bulls look for the right play on Zynga
- What's behind large put selling in DISH
- Yamana Gold